Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis. (9th November 2017)

• Record Type: Journal Article
• Authors: Musgrave, K. M.; Webber, K.; Murphy, P.; Avery, P.; Biss, T. T.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 15:Number 12(2017)
• Page Start: 2361
• Page End: 2366
• Publication Date: 2017-11-09
• Subjects: anticoagulants -- low molecular weight heparin -- pediatrics -- thrombosis -- tinzaparin; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.13856
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract : Essentials The once‐daily dosing of tinzaparin provides an advantage over other low molecular weight heparins. The recommended age‐dependent doses of tinzaparin in children have not previously been validated. Once‐daily administration of tinzaparin is a safe and effective treatment of childhood thrombosis. Recommended doses are appropriate but monitoring may be required due to inter‐individual variation. Summary: Background: The recommended starting doses of tinzaparin for the treatment of thrombosis in children have not previously been validated. There are few data to support the efficacy and safety of once‐daily tinzaparin dosing in children with thrombosis. Objectives: To investigate the use of tinzaparin for the treatment of childhood thrombosis, and to evaluate the age‐dependent dosing recommendations and define outcomes in terms of efficacy and safety. Methods: This was a retrospective cohort study of children aged 0 to < 16 years treated for thrombosis at a large teaching hospital in the UK between 2008 and 2015. Medical records were reviewed to evaluate tinzaparin dosing, anti‐activated factor X (FXa) levels, and patient outcomes. Results: Seventy‐nine children were identified as having received tinzaparin. Dosing information was available for 57. Younger children required higher doses to reach a therapeutic level. The therapeutic dose requirement varied within age groups, supporting the use of anti‐FXa monitoring. Over a median follow‐up of 35 months, there were 13 (16%) bleeding episodes (two major; seven clinically relevant but non‐major; and four minor). There were two (3%) recurrent episodes of thrombosis. Children were treated for a median duration of 3 months, and the majority (86%) remained on tinzaparin for the duration of their anticoagulant therapy. Conclusion: Once‐daily tinzaparin is a safe and effective treatment for childhood thrombosis, with rates of recurrence and bleeding similar to those for other anticoagulants used in children. The recommended starting doses are appropriate, but anti‐FXa monitoring may be required, owing to interindividual variability in the therapeutic dose requirement.